Drug Development Pharma - January 20, 2015
Swiss to Launch Diabetes Drug
Novo Nordisk announced that Switzerland is the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes. Xultophy® is the first combination of a basal insulin [Tresiba® (insulin degludec)] and a GLP-1 analogue [Victoza® (liraglutide)]. Xultophy® is administered as a single injection once a day independently of meals. It is intended for use in adults with type 2 diabetes who […]
Drug Development Pharma - January 12, 2015
FDA OKs Novo Weight-Loss Drug
Two months after its own deadline, the U.S. Food and Drug Administration (FDA) issued approval for Novo Nordisk’s first weight-loss therapy. Approved was Novo’s Saxenda for use in managing weight in conjunction with diet and exercise. Saxenda is a higher dose of the diabetes treatment liraglutide. The drug is indicated for patients who qualify as […]
Acquisition - January 7, 2015
Novo Renews Racing Pact
Novo Nordisk and the Chip Ganassi Racing Teams (CGRT) have inked a multi-year extension of their partnership, renewing Novo Nordisk as the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the Verizon IndyCar Series. Kimball, 29, from Camarillo, California, is the first and only licensed driver with diabetes […]
In a new job - January 6, 2015
Novo’s Soerensen to Step Down
Novo Nordisk’s board likely will begin its search soon for the successor to Chief Executive Officer Lars Rebien Soerensen, who recently announced he will not serve out the rest of his contract to 2019 and could leave his post as early as next year. Among the names mentioned is the company’s President Kaare Schultz, who was […]
Clinical Trials - December 22, 2014
Diabetes Drug Use Expanding
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba®(insulin degludec) in children and adolescents aged 1-17 years with diabetes. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Tresiba® to children with type […]
Collaboration - December 19, 2014
Xencor, Novo Nordisk Team Up
Biopharmaceutical company Xencor, Inc. announced that it has entered a collaboration agreement with Novo Nordisk to discover new drug candidates by combining Xencor XmAb technologies. The research and development deal has the potential to bring in $175 million for Xencor. Both companies will use the bispecific technology to build molecular formats that can target and […]
